- Home
- HBAN vs ILMN Comparison
HBAN vs ILMN Comparison
Compare HBAN & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBAN
- ILMN
- Stock Information
- Founded
- HBAN 1866
- ILMN 1998
- Country
- HBAN United States
- ILMN United States
- Employees
- HBAN N/A
- ILMN N/A
- Industry
- HBAN Major Banks
- ILMN Medical Specialities
- Sector
- HBAN Finance
- ILMN Health Care
- Exchange
- HBAN Nasdaq
- ILMN Nasdaq
- Market Cap
- HBAN 26.0B
- ILMN 16.0B
- IPO Year
- HBAN N/A
- ILMN 2000
- Fundamental
- Price
- HBAN $17.63
- ILMN $100.92
- Analyst Decision
- HBAN Buy
- ILMN Buy
- Analyst Count
- HBAN 17
- ILMN 15
- Target Price
- HBAN $18.84
- ILMN $123.67
- AVG Volume (30 Days)
- HBAN 26.0M
- ILMN 1.3M
- Earning Date
- HBAN 10-16-2025
- ILMN 11-03-2025
- Dividend Yield
- HBAN 3.52%
- ILMN N/A
- EPS Growth
- HBAN 26.38
- ILMN N/A
- EPS
- HBAN 1.34
- ILMN 7.91
- Revenue
- HBAN $7,242,000,000.00
- ILMN $4,284,000,000.00
- Revenue This Year
- HBAN $18.05
- ILMN N/A
- Revenue Next Year
- HBAN $8.22
- ILMN $2.76
- P/E Ratio
- HBAN $13.15
- ILMN $12.64
- Revenue Growth
- HBAN 7.91
- ILMN N/A
- 52 Week Low
- HBAN $11.92
- ILMN $68.70
- 52 Week High
- HBAN $18.45
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- HBAN 57.92
- ILMN 54.31
- Support Level
- HBAN $17.54
- ILMN $95.12
- Resistance Level
- HBAN $17.86
- ILMN $99.56
- Average True Range (ATR)
- HBAN 0.31
- ILMN 3.05
- MACD
- HBAN -0.02
- ILMN -0.04
- Stochastic Oscillator
- HBAN 51.22
- ILMN 98.73
About HBAN Huntington Bancshares Incorporated
Huntington is a regional US bank with around $208 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.